Ception Therapeutics

An FDA advisory committee will discuss the breadth of the proposed indication for Teva Pharmaceutical Industries Ltd. 's biologic asthma treatment Cinqair (reslizumab) and the adequacy of efficac

Steve Tullman, the serial biopharma entrepreneur who sold companies to Actelion, Allergan and Cephalon in the past few years, is starting a new company, Alexar Therapeutics. Malvern, Pennsylvania-base

Actelion Ltd. ’s move to buy U.S. biotech Ceptaris Therapeutics Inc. fits its strategy to buy meaningfully differentiated products that offer value, but do not distract management’s attention from

The market for asthma drugs is heavily saturated with existing products, making the bar high for the safety and efficacy of new treatments. But there is still an unmet need among patients who do not r